Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU

NCT01889862 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Phenylketonuria (PKU)

Interventions

DRUG: BMN165 20mg/day
DRUG: BMN165 40mg/day
DRUG: Placebo

Sponsor

BioMarin Pharmaceutical